In vitro activity of phenothiazines and their combinations with amphotericin B against Zygomycetes causing rhinocerebral zygomycosis

Medical Mycology

Volumn 47, Issue 3, 2009, Pages 331-335

  Galgóczy, László ^a   Papp, Tamás ^a   Kovács, Laura ^a   Ördögh, Lilla ^a   Vágvölgyi, Csaba ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Amphotericin B; Chlorpromazine; Rhinocerebral zygomycosis; Synergism; Trifluoperazine

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CHLORPROMAZINE; TRIFLUOPERAZINE; VORICONAZOLE; ANTIFUNGAL AGENT;

ABSIDIA; ABSIDIA GLAUCA; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BRAIN INFECTION; BRAIN TISSUE; CAUSAL ATTRIBUTION; CEREBROSPINAL FLUID; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FUNGAL MORPHOLOGY; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; NONHUMAN; PLASMA; RHINOCEREBRAL ZYGOMYCOSIS; ZYGOMYCETES; DRUG EFFECT; FUNGUS; HUMAN; ISOLATION AND PURIFICATION; MENINGOENCEPHALITIS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; RHINITIS;

ABSIDIA GLAUCA; FUNGI; ZYGOMYCETES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHLORPROMAZINE; DRUG SYNERGISM; FUNGI; HUMANS; MENINGOENCEPHALITIS; MICROBIAL SENSITIVITY TESTS; RHINITIS; TRIFLUOPERAZINE; ZYGOMYCOSIS;

EID: 66449097364     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802378853     Document Type: Article

References (18)

1. Hsiao YC, Tsan KW, Wang TY. Rhinocerebral mucormycosis in diabetes: A case report. J Intern Med Taiwanu 2002; 13: 160-164.
2. Ribes JA, Vanhover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301.
3. Gallagher CG, Ashley ESD, Drew RH, Perfect JR. Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharm 2003; 4: 147-164.
4. Vicente MF, Basilio A, Cabello A, Pelaez F. Microbial natural products as a source of antifungals. Clin Microbiol Infect 2003; 9: 15-32.
5. Eilam Y, Polacheck I, Gigi GB, Chernichovsky D. Activity of phenothiazines against medically important yeasts. Antimicrob Agents Chemother 1987; 31: 834-836.
6. Wiebe V, Karriker M. Therapy of systemic fungal infections: A pharmacologic perspective. Clin Tech Small Anim Pract 2005; 20 250-257.
7. Molnar J, Mandi Y, Kiraly J. Antimicrobial effect of some phenothiazine compounds and R-factor elimination by chlorpromazine. Acta Microbiol Acad Sci Hun 1976; 23: 45-54.
8. Molnar J, Scheider B. Plasmid curing and antibacterial effects of some chlorpromazine derivatives in relation to their molecule orbitals. Acta Microbiol Acad Sci Hun 1978; 25: 291-298.
9. Motohashni N, Sakagami H, Kurihara T, et al. Antimicrobial activity of phenothiazines, benzo(A) phenothiazines and benz (C)acridines. Anticancer Res 1992; 12: 1207-1210.
10. Motohashni N, Kawase M, Molnar J, et al. Antimicrobial activity of N-acylphenothiazines and their influence on lipid model membranes and erythrocyte membranes. Arzneimittel-Forschung-Drug Res 2003; 53 590-599.
11. Wood NC, Nugent KM. Inhibitory effects of chlorpromazine on candida species. Antimicrob Agents Chemother 1985; 27: 692-694.
12. Wang Y, Casadevall A. Susceptibility of melanized and nonmelanized Cryptococcus neoformans to the melanin-binding compounds trifluoperazine and chloroquine. Antimicrob Agents Chemother 1996; 40: 541-545.
13. Afeltra J, Verweij PE. Antifungal activity of nonantifungal drugs. Eur J Clin Microbiol Infect Dis 2003; 22: 397-407.
14. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. NCCLS document M38-A. NCCLS, Wayne, Pennsylvania, USA, 2002.
15. Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: Lorian V (ed.). Antibiotics in Laboratory Medicine. 4th ed. Baltimore, MD: Williams and Wilkins, 1996. pp 330-396.
16. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
17. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of Zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51 2587-2590.
18. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans Infection of the central nervous system JID 2000; 182: 274-282.